Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,deferredLongTermLiab,treasuryStock,otherStockholderEquity,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,netBorrowings,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,INBX,60593000.0,37810800,,,-19287000,,-19289000,3009000,-15549000,-18558000,-18558000,,-745000,,,,2000,889000,19447000,16438000,-729000,,-19289000,-19289000,225257000.0,63911000.0,60593000.0,4075000.0,124504000.0,4000.0,5055000.0,-164668000.0,310000.0,245000.0,107990000.0,27850000.0,10857000.0,113402000.0,357000.0,29445000.0,14291000.0,,,,1047000.0,-14000.0,988000.0,-7727000.0,988000.0,-20674000.0,-21648000.0,291000.0,46000.0,3783000.0,-14000.0,,,85552000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1.4375871,28.0 - 30.48,28.52,0.0,0.0,8,9,finmb_563995161,NasdaqGM,"Inhibrx, Inc.",USD,211870,83828,14.66,1.02733,14.27 - 50.97,-22.04,-0.43241122,14.27,50.97,1620922202,1620922202,1620922202,-14400000,False,False,USD,PRE,-2.39,-12.104602,28.407429,0.52257156,0.018395595,23.858116,5.071884,0.21258527,1093866496,15,America/New_York,EDT,"Inhibrx, Inc.",28.93,1630526403,0.40999985,28.64,30.48,28.0,102134,0,NGM,2,us_market,,,,50.97,14.27,28.41,23.86,211.87k,83.83k,37.81M,,17.36M,40.06%,43.12%,779.1k,5.77,3.47%,2.06%,837.14k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-529.95%,-58.63%,-567.79%,12.9M,0.43,1.90%,-60.61M,-67.34M,-75.32M,,,107.99M,2.86,37.3M,61.55,4.07,,-62.23M,,Value,92037,Healthcare,84,8,4,"Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.",La Jolla,858 795 4220,CA,8,1609372800,1622505600,10,United States,http://inhibrx.com,86400,9,11025 North Torrey Pines Road,Biotechnology,Suite 200
t-1,INBX,75473000.0,37810800,,,-17646000,,-17649000,2215000,-14892000,-17107000,-17107000,,-532000,,,,3000,2776000,19883000,17668000,-539000,,-17649000,-17649000,220848000.0,68267000.0,75473000.0,3081000.0,143740000.0,4000.0,2893000.0,-145379000.0,917000.0,245000.0,128664000.0,31399000.0,11323000.0,132172000.0,615000.0,29244000.0,13458000.0,,,,-2707000.0,-612000.0,16996000.0,2233000.0,23000.0,995000.0,-15389000.0,265000.0,599000.0,1727000.0,-612000.0,18105000.0,-1132000.0,100773000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1.4375871,28.0 - 30.48,28.52,0.0,0.0,8,9,finmb_563995161,NasdaqGM,"Inhibrx, Inc.",USD,211870,83828,14.66,1.02733,14.27 - 50.97,-22.04,-0.43241122,14.27,50.97,1620922202,1620922202,1620922202,-14400000,False,False,USD,PRE,-2.39,-12.104602,28.407429,0.52257156,0.018395595,23.858116,5.071884,0.21258527,1093866496,15,America/New_York,EDT,"Inhibrx, Inc.",28.93,1630526403,0.40999985,28.64,30.48,28.0,102134,0,NGM,2,us_market,,,,50.97,14.27,28.41,23.86,211.87k,83.83k,37.81M,,17.36M,40.06%,43.12%,779.1k,5.77,3.47%,2.06%,837.14k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-529.95%,-58.63%,-567.79%,12.9M,0.43,1.90%,-60.61M,-67.34M,-75.32M,,,107.99M,2.86,37.3M,61.55,4.07,,-62.23M,,Value,92037,Healthcare,84,8,4,"Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.",La Jolla,858 795 4220,CA,8,1609372800,1622505600,10,United States,http://inhibrx.com,86400,9,11025 North Torrey Pines Road,Biotechnology,Suite 200
t-2,INBX,91729000.0,37810800,,,-20497000,,-20497000,1622000,-13936000,-15558000,-15558000,,-4428000,,,,0,5901000,21459000,19837000,-4939000,,-20497000,-20497000,219455000.0,51825000.0,91729000.0,5176000.0,143554000.0,4000.0,3217000.0,-127730000.0,170000.0,245000.0,127669000.0,34737000.0,11459000.0,131850000.0,964000.0,9821000.0,15186000.0,,,,5654000.0,-299000.0,136218000.0,-4993000.0,136854000.0,122037000.0,-13882000.0,249000.0,-676000.0,2159000.0,-299000.0,9958000.0,-10594000.0,97113000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1.4375871,28.0 - 30.48,28.52,0.0,0.0,8,9,finmb_563995161,NasdaqGM,"Inhibrx, Inc.",USD,211870,83828,14.66,1.02733,14.27 - 50.97,-22.04,-0.43241122,14.27,50.97,1620922202,1620922202,1620922202,-14400000,False,False,USD,PRE,-2.39,-12.104602,28.407429,0.52257156,0.018395595,23.858116,5.071884,0.21258527,1093866496,15,America/New_York,EDT,"Inhibrx, Inc.",28.93,1630526403,0.40999985,28.64,30.48,28.0,102134,0,NGM,2,us_market,,,,50.97,14.27,28.41,23.86,211.87k,83.83k,37.81M,,17.36M,40.06%,43.12%,779.1k,5.77,3.47%,2.06%,837.14k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-529.95%,-58.63%,-567.79%,12.9M,0.43,1.90%,-60.61M,-67.34M,-75.32M,,,107.99M,2.86,37.3M,61.55,4.07,,-62.23M,,Value,92037,Healthcare,84,8,4,"Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.",La Jolla,858 795 4220,CA,8,1609372800,1622505600,10,United States,http://inhibrx.com,86400,9,11025 North Torrey Pines Road,Biotechnology,Suite 200
t-3,INBX,-93569000.0,37810800,,,-20093000,,-20093000,1467000,-16144000,-17611000,-17611000,,-2451000,,,,0,872000,18483000,17016000,-2482000,,-20093000,-20093000,,88338000.0,-93569000.0,4106000.0,21301000.0,2000.0,3044000.0,-107233000.0,4548000.0,771000.0,5632000.0,29775000.0,11732000.0,8798000.0,122000.0,46533000.0,8909000.0,500000.0,-19313000.0,-19313000.0,5431000.0,-91000.0,-3633000.0,3813000.0,136854000.0,-11112000.0,-7388000.0,256000.0,199000.0,1462000.0,-91000.0,-3583000.0,-50000.0,-20977000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1.4375871,28.0 - 30.48,28.52,0.0,0.0,8,9,finmb_563995161,NasdaqGM,"Inhibrx, Inc.",USD,211870,83828,14.66,1.02733,14.27 - 50.97,-22.04,-0.43241122,14.27,50.97,1620922202,1620922202,1620922202,-14400000,False,False,USD,PRE,-2.39,-12.104602,28.407429,0.52257156,0.018395595,23.858116,5.071884,0.21258527,1093866496,15,America/New_York,EDT,"Inhibrx, Inc.",28.93,1630526403,0.40999985,28.64,30.48,28.0,102134,0,NGM,2,us_market,,,,50.97,14.27,28.41,23.86,211.87k,83.83k,37.81M,,17.36M,40.06%,43.12%,779.1k,5.77,3.47%,2.06%,837.14k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-529.95%,-58.63%,-567.79%,12.9M,0.43,1.90%,-60.61M,-67.34M,-75.32M,,,107.99M,2.86,37.3M,61.55,4.07,,-62.23M,,Value,92037,Healthcare,84,8,4,"Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.",La Jolla,858 795 4220,CA,8,1609372800,1622505600,10,United States,http://inhibrx.com,86400,9,11025 North Torrey Pines Road,Biotechnology,Suite 200
